Abstracts tagged "MicroRNA and atherosclerosis"

Abstract Number: 1934 • 2018 ACR/ARHP Annual Meeting
microRNA Targeting IL-33 Gene As Biomarker to Predict Subclinical Atherosclerosis in Patients with Early Rheumatoid Arthritis
Isaac T. Cheng¹, Qing Shang², Jiayun Shen³, Martin Li³, Queenie Mak², Kitty Y Kwok⁴, Isaac CW Yim⁵, Edmund Kwok Ming Li², Priscilla Wong¹, Ronald ML Yip⁶, Steve H Pang⁶ and Lai-Shan Tam⁷, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁵Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ⁶Department of Medicine, Kwong Wah Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong
Background/Purpose: Patients with RA had increased risk of cardiovascular disease (CVD). Interleukin 33 (IL-33) plays an important role in pathogenesis of RA and development of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].